drugset / Trial / NCT00693485
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
RandomizedParallel-groupTriple-blindTreatment
Summary
A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. Patients will be followed for up to 1 year.
Timeline
- Start
- 2008-09
- Primary completion
- 2011-01
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brimonidine | Small molecule | 200 ug | Intravitreal |
| Subject | Brimonidine | Small molecule | 400 ug | Intravitreal |